HORIZON THERAPEUTICS PLC (HZNP) Stock Price, Quote, News and Overview
NASDAQ:HZNP - Nasdaq - IE00BQPVQZ61 - Common Stock - Currency: USD
HZNP Quote, Performance and Key Statistics
116.3
+0.05 (+0.04%)
The current stock price of HZNP is 116.3 USD. In the past month the price increased by 0.77%. In the past year, price increased by 78.92%.
HZNP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About HZNP
Company Profile
Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 2,190 full-time employees. The company went IPO on 2010-08-11. The firm is focused on the discovery, development and commercialization of medicines that address the critical needs of people impacted by rare, autoimmune and severe inflammatory diseases. The Company’s portfolio of medicines include ACTIMMUNE, BUPHENYL (sodium phenylbutyrate), KRYSTEXXA pegloticase, PROCYSBI (cysteamine bitartrate), Prescription RAVICTI (glycerol phenylbutyrate), TEPEZZA teprotumumab-trbw and other. ACTIMMUNE is part of a drug regimen used to treat Chronic Granulomatous Disease (CGD). BUPHENYL (sodium phenylbutyrate) is a tablet for oral administration and BUPHENYL (sodium phenylbutyrate) Powder for oral, nasogastric, or gastrostomy tube administration contains sodium phenylbutyrate. PROCYSBI (cysteamine bitartrate) delayed-release capsules and delayed-release oral granules is a prescription medicine used to treat nephropathic cystinosis in adults and children 1 year of age and older.
Company Info
HORIZON THERAPEUTICS PLC
70 St. Stephen's Green, Saint Kevin's, Dublin 2
DUBLIN DUBLIN D04 C5Y6 IE
CEO: Timothy Walbert
Employees: 2190
Company Website: https://www.horizontherapeutics.com/
Phone: 35317722100.0
HORIZON THERAPEUTICS PLC / HZNP FAQ
What is the stock price of HORIZON THERAPEUTICS PLC today?
The current stock price of HZNP is 116.3 USD. The price increased by 0.04% in the last trading session.
What is the ticker symbol for HORIZON THERAPEUTICS PLC stock?
The exchange symbol of HORIZON THERAPEUTICS PLC is HZNP and it is listed on the Nasdaq exchange.
On which exchange is HZNP stock listed?
HZNP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for HORIZON THERAPEUTICS PLC stock?
11 analysts have analysed HZNP and the average price target is 118.83 USD. This implies a price increase of 2.18% is expected in the next year compared to the current price of 116.3. Check the HORIZON THERAPEUTICS PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HORIZON THERAPEUTICS PLC worth?
HORIZON THERAPEUTICS PLC (HZNP) has a market capitalization of 26.63B USD. This makes HZNP a Large Cap stock.
How many employees does HORIZON THERAPEUTICS PLC have?
HORIZON THERAPEUTICS PLC (HZNP) currently has 2190 employees.
What are the support and resistance levels for HORIZON THERAPEUTICS PLC (HZNP) stock?
HORIZON THERAPEUTICS PLC (HZNP) has a support level at 115.88 and a resistance level at 116.31. Check the full technical report for a detailed analysis of HZNP support and resistance levels.
Is HORIZON THERAPEUTICS PLC (HZNP) expected to grow?
The Revenue of HORIZON THERAPEUTICS PLC (HZNP) is expected to grow by 5.55% in the next year. Check the estimates tab for more information on the HZNP EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy HORIZON THERAPEUTICS PLC (HZNP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HZNP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HZNP, evaluating the profitability, health, valuation and growth aspects
- HORIZON THERAPEUTICS PLC (HZNP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HORIZON THERAPEUTICS PLC (HZNP) Sales and EPS estimates to see what analysts future expectations are.
- HORIZON THERAPEUTICS PLC (HZNP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HORIZON THERAPEUTICS PLC (HZNP) Insider and Institutional Ownership to learn about the owners and their transactions.
- HORIZON THERAPEUTICS PLC (HZNP) Stock Chart to make your own analysis
- HORIZON THERAPEUTICS PLC (HZNP) Latest news and press-releases to stay up to date.
Does HORIZON THERAPEUTICS PLC (HZNP) stock pay dividends?
HZNP does not pay a dividend.
What is the Price/Earnings (PE) ratio of HORIZON THERAPEUTICS PLC (HZNP)?
The PE ratio for HORIZON THERAPEUTICS PLC (HZNP) is 25.9. This is based on the reported non-GAAP earnings per share of 4.49 and the current share price of 116.3 USD. Check the full fundamental report for a full analysis of the valuation metrics for HZNP.
HZNP Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to HZNP. When comparing the yearly performance of all stocks, HZNP is one of the better performing stocks in the market, outperforming 96.67% of all stocks.
HZNP Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to HZNP. HZNP gets an excellent profitability rating and is at the same time showing great financial health properties.
HZNP Financial Highlights
Over the last trailing twelve months HZNP reported a non-GAAP Earnings per Share(EPS) of 4.49. The EPS decreased by -19.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.02% | ||
| ROA | 4.71% | ||
| ROE | 8.25% | ||
| Debt/Equity | 0.48 |
HZNP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 51% to HZNP. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -5.01% and a revenue growth 5.55% for HZNP